Akebia Therapeutics, Inc. - Common Stock (AKBA)
CUSIP: 00972D105
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 263,222,327
- Total 13F shares
- 67,845,406
- Share change
- +8,399,079
- Total reported value
- $128,903,910
- Put/Call ratio
- 406%
- Price per share
- $1.90
- Number of holders
- 120
- Value change
- +$16,367,542
- Number of buys
- 67
- Number of sells
- 32
Quarterly Holders Quick Answers
What is CUSIP 00972D105?
CUSIP 00972D105 identifies AKBA - Akebia Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00972D105:
Top shareholders of AKBA - Akebia Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
5.8%
|
15,197,207
|
$20,060,314 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
10,070,298
|
$13,292,793 | — | 30 Sep 2024 | |
| Muneer A. Satter |
13D/G
|
Satter Muneer A |
2.6%
|
5,747,906
|
$13,105,226 | $0 | 31 Dec 2024 | |
| Alerce Investment Management, L.P. |
13F
|
Company |
2.2%
|
5,747,906
|
$7,587,236 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
4,754,464
|
$6,276,831 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.4%
|
3,717,800
|
$4,907,496 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
3,430,527
|
$4,528,296 | — | 30 Sep 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.77%
|
2,034,169
|
$2,685,103 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.62%
|
1,635,099
|
$2,158,331 | — | 30 Sep 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.5%
|
1,323,729
|
$1,747,322 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.41%
|
1,088,892
|
$1,437,337 | — | 30 Sep 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.4%
|
1,046,691
|
$1,381,632 | — | 30 Sep 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.33%
|
868,021
|
$1,145,787 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0.26%
|
682,038
|
$900,291 | — | 30 Sep 2024 | |
| Ellen Snow |
3/4/5
|
SVP, CFO and Treasurer |
—
mixed-class rows
|
743,300
mixed-class rows
|
$872,424 | — | 31 Jan 2024 | |
| Michel Dahan |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
896,092
mixed-class rows
|
$846,836 | — | 13 May 2024 | |
| Nicole R. Hadas |
3/4/5
|
SVP, Chief Legal Officer |
—
mixed-class rows
|
875,243
mixed-class rows
|
$820,566 | — | 13 May 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
568,667
|
$750,640 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.18%
|
485,269
|
$640,555 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.18%
|
469,708
|
$620,014 | — | 30 Sep 2024 | |
| David A. Spellman |
3/4/5
|
SVP, CFO and Treasurer |
—
class O/S missing
|
446,483
|
$546,004 | — | 16 May 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.15%
|
404,718
|
$534,228 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.14%
|
380,535
|
$502,306 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.1%
|
273,085
|
$360,472 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.09%
|
249,573
|
$329,435 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.09%
|
242,876
|
$320,589 | — | 30 Sep 2024 | |
| Violetta Cotreau |
3/4/5
|
SVP, Chief Accounting Officer |
—
class O/S missing
|
219,954
|
$268,982 | — | 12 May 2022 | |
| SAPIENT CAPITAL LLC |
13F
|
Company |
0.08%
|
200,000
|
$264,000 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.07%
|
187,849
|
$247,961 | — | 30 Sep 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.06%
|
170,374
|
$224,893 | — | 30 Sep 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.06%
|
167,184
|
$220,683 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.06%
|
164,570
|
$217,232 | — | 30 Sep 2024 | |
| Dell J. Faulkingham |
3/4/5
|
SVP, CCO |
—
mixed-class rows
|
373,841
mixed-class rows
|
$212,590 | — | 28 Feb 2022 | |
| UBS Group AG |
13F
|
Company |
0.06%
|
153,662
|
$202,833 | — | 30 Sep 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.06%
|
151,405
|
$199,855 | — | 30 Sep 2024 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.05%
|
142,274
|
$187,802 | — | 30 Sep 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.05%
|
141,049
|
$186,185 | — | 30 Sep 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.05%
|
140,167
|
$185,020 | — | 30 Sep 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.05%
|
133,934
|
$177,000 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.05%
|
126,648
|
$168,000 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.05%
|
123,728
|
$163,321 | — | 30 Sep 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.05%
|
119,774
|
$158,102 | — | 30 Sep 2024 | |
| Creative Planning |
13F
|
Company |
0.04%
|
116,172
|
$153,347 | — | 30 Sep 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.04%
|
114,148
|
$150,675 | — | 30 Sep 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.04%
|
111,229
|
$146,822 | — | 30 Sep 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.04%
|
110,385
|
$145,708 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.04%
|
99,298
|
$131,073 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.04%
|
98,546
|
$130,081 | — | 30 Sep 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.04%
|
93,350
|
$122,000 | — | 30 Sep 2024 | |
| TD Waterhouse Canada Inc. |
13F
|
Company |
0.03%
|
90,618
|
$114,976 | — | 30 Sep 2024 |
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2024
As of 31 Dec 2024,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
120 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,845,406 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, Alerce Investment Management, L.P., GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, NORTHERN TRUST CORP, CITADEL ADVISORS LLC, and JACOBS LEVY EQUITY MANAGEMENT, INC.
This page lists
120
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
113
Q4 2024 holders
120
Holder diff
7
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.